Exploratory cohort study and meta-analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

References

• ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
   PubMed Web of Science ®Google Scholar
• CostaDBHalmosBKumarABIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutationsPLoS Med200741016691679 discussion 168017973572
   PubMed Web of Science ®Google Scholar
• NiJZhangLEvaluation of three small molecular drugs for targeted therapy to treat nonsmall cell lung cancerChin Med J (Engl)2016129333234026831237
   PubMedGoogle Scholar
• MaemondoMInoueAKobayashiKNorth-East Japan Study GroupGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• AokiTIgawaSFuruyaNImpacts of treatment lines and initiation timing of erlotinib for advanced non-small cell lung cancerAnticancer Res201232260160822287751
   PubMedGoogle Scholar
• MitsudomiTMoritaSYatabeYWest Japan Oncology GroupGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• HuangWFLiuAHZhaoHJDongHMLiuLYCaiSXBIM gene polymorphism lowers the efficacy of EGFR-TKIs in advanced non small cell lung cancer with sensitive EGFR mutations: a systematic review and meta-analysisMedicine (Baltimore)20159433e126326287412
   PubMedGoogle Scholar
• PaoWChmieleckiJRational, biologically based treatment of EGFR-mutant non-small-cell lung cancerNat Rev Cancer2010101176077420966921
   PubMed Web of Science ®Google Scholar
• FordePMEttingerDSManaging acquired resistance in EGFR-mutated non-small cell lung cancerClin Adv Hematol Oncol201513852853226351816
   PubMedGoogle Scholar
• WangSCangSLiuDThird-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancerJ Hematol Oncol201693427071706
   PubMed Web of Science ®Google Scholar
• WangSTsuiSTLiuCSongYLiuDEGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancerJ Hematol Oncol2016915927448564
   PubMed Web of Science ®Google Scholar
• WangSSongYYanFLiuDMechanisms of resistance to third-generation EGFR tyrosine kinase inhibitorsFront Med201610438338827770386
   PubMed Web of Science ®Google Scholar
• NgKPHillmerAMChuahCTA common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancerNat Med201218452152822426421
   PubMed Web of Science ®Google Scholar
• O’ConnorLStrasserAO’ReillyLABim: a novel member of the Bcl-2 family that promotes apoptosisEMBO J19981723843959430630
   PubMed Web of Science ®Google Scholar
• NakagawaTTakeuchiSYamadaTEGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibitionCancer Res20137382428243423382048
   PubMed Web of Science ®Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• PaezJGJännePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience200430456761497150015118125
   PubMed Web of Science ®Google Scholar
• YiSZhuangYZhouJA comparison of epidermal growth factor receptor mutation testing methods in different tissue types in non-small cell lung cancerInt J Mol Med201434246447424891042
   PubMedGoogle Scholar
• BeggCBMazumdarMOperating characteristics of a rank correlation test for publication biasBiometrics1994504108811017786990
   PubMed Web of Science ®Google Scholar
• EggerMDavey SmithGSchneiderMMinderCBias in meta-analysis detected by a simple, graphical testBMJ199731571096296349310563
   PubMed Web of Science ®Google Scholar
• LeeJKShinJYKimSPrimary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory studyAnn Oncol20132482080208723559152
   PubMed Web of Science ®Google Scholar
• ZhengLLinBSongZRelationship between BIM gene polymorphism and therapeutic efficacy in the retreatment of advanced non-small cell lung cancer with tyrosine kinase inhibitorZhongguo Fei Ai Za Zhi20131612632638 Chinese [with English abstract]24345487
   PubMedGoogle Scholar
• CostaCMolinaMADrozdowskyjAThe impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trialClin Cancer Res20142072001201024493829
   PubMed Web of Science ®Google Scholar
• ZhongJLiZXZhaoJAnalysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patientsThorac Cancer20145650951626767045
   PubMedGoogle Scholar
• IsobeKHataYTochigiNClinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutationJ Thorac Oncol20149448348724736070
   PubMed Web of Science ®Google Scholar
• ZhaoMZhangYCaiWThe Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancerCancer2014120152299230724737648
   PubMed Web of Science ®Google Scholar
• LeeJHLinYLHsuWHBcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancerJ Thorac Oncol2014991385139225057939
   PubMedGoogle Scholar
• LeeJYKuBMLimSHThe BIM deletion polymorphism and its clinical implication in patients with EGFR-mutant non-small-cell lung cancer treated with EGFR tyrosine kinase inhibitorsJ Thorac Oncol201510690390926001141
   PubMedGoogle Scholar
• WellsGASheaBO’ConnellDThe Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysesOttawa, ONOttawa Hospital Research Institute2011 Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htmAccessed January 1, 2011
   Google Scholar
• XiaJJZhaoSFXiongLWReal-time PCR assay with high resolution melting for EGFR and BIM mutation of lung cancerEur Rev Med Pharmacol Sci201620132805281127424979
   PubMedGoogle Scholar
• NieWTaoXWeiHChenWSLiBThe BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: a systematic review and meta-analysisOncotarget2015628256962570026325082
   PubMedGoogle Scholar
• ZouQZhanPLvTSongYThe relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysisTransl Lung Cancer Res20154679279626798589
   PubMedGoogle Scholar
• YingHQChenJHeBSThe effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapySci Rep201551134826076815
   PubMedGoogle Scholar
• MaJYYanHLGuWAssociation between BIM deletion polymorphism and clinical outcome of EGFR-mutated NSCLC patient with EGFR-TKI therapy: a meta-analysisJ Cancer Res Ther201511239740226148607
   PubMed Web of Science ®Google Scholar
• LeeJYLimSHKimMIs there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?Cancer Chemother Pharmacol20147351063107024663503
   PubMedGoogle Scholar
• HsiaoSHLiuHELeeHLDistinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus respondersPLoS One2013812e8326624376677
   PubMed Web of Science ®Google Scholar